Utilizing Drug Names to Uncover Related Biological Sequences for Drug Development
31 August 2023
The Center for Drug Evaluation, NMPA (CDE) shows that the application for the listing of Overland Pharmaceutical's CD19 antibody-drug conjugate (ADC), Loncastuximab, has been accepted. This is also the first China-reported ADC targeting CD19. CD19 is a popular target in the development of antitumor drugs. If Loncastuximab is approved, multiple types of drugs, including monoclonal antibodies, bispecific antibodies, CAR-T cells, and ADCs, will fulfill this target. We take Loncastuximab as an example to retrieve its related biological sequences.